Patient-reported benefits of colonoscopicallyadministered microbiota restoration therapy: a qualitative study of adult patients with recurrent <i>Clostridioides difficile</i> infection.

ABSTRACT:

Background

Recurrent Clostridioides difficile infection (rCDI) disrupts health-related quality of life (HRQoL), often causing debilitating symptoms, emotional distress, and social withdrawal. Fecal microbiota, live-jslm (RBL; REBYOTA^®) is approved by the FDA to reduce CDI recurrence. While the burden of rCDI is well established, less is known about the patient experience after RBL treatment and its impact on HRQoL.

Objectives

To explore the burden of rCDI on HRQoL, and any improvements in symptoms and impacts after RBL administration by colonoscopy.

Design

A qualitative sub-study embedded in the CDI-SCOPE phase IIIb clinical trial (NCT05831189).

Methods

Qualitative interviews were conducted with 30 trial participants approximately 8 weeks afte

SUBMITTER: McCool-Myers M 

PROVIDER: S-EPMC12868591 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature